Arrowhead Research | ARWR - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 41.74M 4.28M 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Incyte USD 351.73M 23.64M 2026-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Ligand Pharmaceuticals USD 20.84M 4.19M 2026-03
Merck USD 2.67B 180M 2026-03
Moderna USD 216M 43M 2026-06
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Novartis USD 3.24B 101M 2026-06
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
TG Therapeutics USD 73.14M 22.42M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03
Xencor USD 82.12M 65.08M 2026-03